FDA Approves First Drug for Genetic Cause of Dwarfism

FDA Approves First Drug for Genetic Cause of Dwarfism
David Proeber/The Pantagraph via AP

The Food and Drug Administration approved the first treatment for the most common cause of dwarfism Friday, a drug that has proved to increase children’s height but has been polarizing among adults with short stature.

The treatment, developed by BioMarin Pharmaceutical, is a once-daily injection for children with achondroplasia, a rare genetic disorder that results in dwarfism and can lead to serious medical complications

Read Full Article »


Comment
Show comments Hide Comments


Related Articles